EHRA Premium Access

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - PRO

Congress Presentation

About the speaker

Professor Vincent Probst

University Hospital of Nantes, Nantes (France)
8 presentations
0 follower

11 more presentations in this session

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - CON

Speaker: Professor S. Viskin (Tel Aviv, IL)

Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal PRO

Thumbnail

Ablation should be 1st line therapy in the high risk Brugada Syndrome patient - Rebuttal CON

Thumbnail

Chairperson conclusion & Closing question

Thumbnail

Access the full session

Controversies in channelopathy

Speakers: Professor V. Probst, Professor S. Viskin
Thumbnail

About the event

Image

EHRA 2018

18 March - 20 March 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb